CRBN and plasma cell myeloma: IMiDs, such as lenalidomide or pomalidomide, mediate their anti-myeloma activity and, particularly, immunomodulatory activity via cereblon; CELMoDs, therefore, are novel and functionally different cereblon-targeting agents which lead to myeloma cell apoptosis and stimulate the immune system, and they could help overcome resistance to certain drugs.